The pharmacological inhibition of PDE2A has been evaluated in preclinical studies, thus suggesting PDE2A inhibitors as a potential treatment for neurodegenerative diseases, such as Alzheimer’s disease, schizophrenia, and dementia [15,16]. Here, PDE2A is linked to schizophrenia.